Drugs / FF-10101-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03194685 | May 2017 → Jul 2021 | acute myeloid leukemia | Fujifilm Pharmaceuticals U.S.A., Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FF-10101-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03194685 ↗ |
| Action | Inhibit | “FF-10101 is a novel compound that covalently binds to a cysteine residue near the active site of FLT3, irreversibly inhibiting receptor signaling.” PMID 38502195 ↗ May 2024 |
| Modality | Small molecule | “FF-10101 is a novel compound that covalently binds to a cysteine residue near the active site of FLT3” PMID 38502195 ↗ May 2024 |
| Route | Oral | “FF-10101-01 will be administered orally once a day on Days 1-28 of a 28-day cycle.” NCT03194685 ↗ |
| Target | FLT3 | “covalently binds to a cysteine residue near the active site of FLT3” PMID 38502195 ↗ May 2024 |